Legend Biotech’s Q1 2026 EPS of -$0.15 fell short of the $0.01 forecast. Revenue reached $305.1 million, slightly below expectations. The stock surged 12.08% pre-market despite the earnings miss.

Good morning, everybody. We're waiting for the few final people to pop into the conference, and we'll get started in just a few seconds. Everybody has joined the conference. So Randy, good to go.

Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a ...

Gross margins improved dramatically from 21% to 41% year-over-year. Operating expenses were reduced by 35% compared to the previous year. Revenue grew by 4.2% quarter-over-quarter, reaching CAD ...

Earnings call Legend Power Systems reported Q2 FY2025 revenue of $523,000, up 322% YoY, with gross margin dollars doubling despite margin percentage declining to 22% due to product mix and component ...

Read LEGEND POWER SYSTEMS INC (LPS.NE) Q4 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...

Revenue: CAD 545,000, up 4.2% from CAD 523,000 in Q1 2026. Gross Margin: 41%, a significant increase from 21% year-over-year. Operating Expenses: CAD 658,000, down 35% from Q2 2025. Inventory ...

Legend Biotech (LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 11th, before market open. The consensus EPS Estimate is -$0.12 (+64.7% Y/Y) and the consensus Revenue Estimate ...